Aptevo Therapeutics Inc. (APVO) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-26

How it makes money

Future income relies on receiving milestone payments when a partner commercializes a specific drug.

The company expects income from Medexus. These payments occur because Medexus successfully develops, markets, and commercializes IXINITY.

What protects it: the moat

Management asserts that its proprietary protein platforms allow for efficient drug design.

The company uses its ADAPTIR and ADAPTIR-FLEX platforms to create molecules. These modular platforms are intended to provide flexibility in generating various immunotherapeutic candidates.

What growth costs

It will require substantial resources to discover, develop, and commercialize its candidates.

The company expects to incur annual net operating losses for the foreseeable future. It must fund the expansion of its efforts to develop new drugs.

What could damage it

If Medexus fails to market IXINITY, the company loses its anticipated milestone payments.

The company's income is tied to the success of its partner. If Medexus cannot successfully commercialize IXINITY, the resulting milestone payments will not be paid to the company.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Other companies in Biotechnology